First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma

被引:5
|
作者
Wang, Xuechen [1 ,2 ]
Haaland, Benjamin [1 ,2 ]
Hu-Lieskovan, Siwen [1 ,3 ]
Colman, Howard [1 ,4 ]
Holmen, Sheri L. [1 ,5 ,6 ]
机构
[1] Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Dept Populat Hlth Sci, Salt Lake City, UT USA
[3] Univ Utah, Dept Internal Med, Hlth Sci Ctr, Salt Lake City, UT 84112 USA
[4] Univ Utah, Hlth Sci Ctr, Dept Neurosurg, Salt Lake City, UT USA
[5] Univ Utah, Dept Surg, Hlth Sci Ctr, 2000 Circle Hope, Salt Lake City, UT 84112 USA
[6] Univ Utah, Hlth Sci Ctr, Dept Oncol Sci, Salt Lake City, UT USA
关键词
first line therapy; immunology; melanoma; metastasis; target therapy; DABRAFENIB PLUS TRAMETINIB; STAGE-III; MEK INHIBITION; DOUBLE-BLIND; OPEN-LABEL; IPILIMUMAB; NIVOLUMAB; MULTICENTER; THERAPY; PLACEBO;
D O I
10.1002/cnr2.1419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Recent advances in targeted therapy and immunotherapy have improved the prognosis of melanoma patients but brain metastasis remains a major challenge. Currently, it is unclear how existing therapies can be best used to prevent or treat brain metastasis in melanoma patients. Aims We aimed to assess brain metastasis free survival (BMFS), overall survival (OS), incidence of brain metastases, and sequencing strategies of immunotherapy and targeted therapy in patients with BRAF-mutated advanced melanoma. Methods and results We retrospectively analyzed 683 patients with BRAF-mutated advanced melanoma treated with first line (1L) immunotherapy (N = 266) or targeted therapy (N = 417). The primary outcome was BMFS. Secondary outcomes included OS of all patients and incidence of brain metastases in patients without documented brain metastases prior to 1L therapy. The median BMFS was 13.7 months [95% confidence interval (CI): 12.4-16.0] among all patients. The median BMFS for patients receiving 1L immunotherapy was 41.9 months [95% CI: 22.8-not reached (NR)] and targeted therapy was 11.0 months (95% CI: 8.8-12.5). Median OS results were qualitatively similar to BMFS results. The cumulative incidence of brain metastases for patients receiving 1L targeted therapy was higher than for patients receiving 1L immunotherapy (P < .001). Patients receiving 1L anti-CTLA4 plus anti-PD1 combination immunotherapy only or followed by second line (2L) targeted therapy had better BMFS (HR 0.40, 95% CI: 0.24-0.67, P = .001), improved OS (HR 0.49, 95% CI: 0.30-0.81, P = .005), and reduced incidence of brain metastases (HR 0.47, 95% CI: 0.24-0.67, P = .047) than patients receiving 1L combination BRAF and MEK targeted therapy followed by 2L immunotherapy. Conclusion Patients with advanced BRAF mutant melanoma treated with 1L immunotherapy have significantly longer BMFS and OS, and reduced incidence of brain metastases, compared with those treated with 1L targeted therapy. Further studies evaluating the ability of immunotherapy and targeted therapy to improve OS and prevent brain metastases are warranted
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Incidence of Radiation Necrosis in Brain Metastasis Patients Treated with Stereotactic Radiosurgery and Immunotherapy
    Glenn, Chase
    Hughes, Ryan
    Lanier, Claire
    Dohm, Ammoren
    Ruiz, Jimmy
    Triozzi, Pierre
    Cramer, Christina
    Tatter, Stephen
    Laxton, Adrian
    Xing, Fei
    Lo, Hui-Wen
    Su, Jing
    Watabe, Kounosuke
    Wang, Ge
    Chan, Michael
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (05): : E50 - E50
  • [42] BRAIN METASTASIS FROM ADVANCED GASTRIC CANCERS: HIGH INCIDENCE OF LEPTOMENINGEAL DISSEMINATION AND ITS CLINICAL IMPACT ON SURVIVAL
    Kim, Euihyun
    NEURO-ONCOLOGY, 2024, 26
  • [43] Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability
    Chen, Chih-Wen
    Ou, Tao-Shen
    Chen, Wei-Shone
    Jiang, Jeng-Kai
    Yang, Shung-Haur
    Wang, Huann-Sheng
    Chang, Shih-Ching
    Lan, Yuan-Tzu
    Lin, Chun-Chi
    Lin, Hung-Hsin
    Huang, Sheng-Chieh
    Cheng, Hou-Hsuan
    Yang, Yi-Wen
    Lin, Yu-Zu
    Chao, Yee
    Wang, Ling-Wei
    Teng, Hao-Wei
    CLINICAL COLORECTAL CANCER, 2023, 22 (03) : 267 - 279
  • [44] Impact of immunotherapy on intracranial progression-free survival in patients with advanced lung cancer and melanoma with brain metastasis: A single-center retrospective study and comparison of the pre- and post-immunotherapy era.
    Kim, Do Young
    Mohammadi, Oranus
    Omenuko, Nnamdi J.
    Sant, Ashley
    Lewis, Nicole
    Jaishankar, Devapiran
    Chakraborty, Kanishka
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Treatment and survival of patients with small cell lung cancer and brain metastasis
    Chi-Lu Chiang
    Huai-Che Yang
    Ying-Ting Liao
    Yung-Hung Luo
    Yuan-Hung Wu
    Hsiu-Mei Wu
    Yuh-Min Chen
    Journal of Neuro-Oncology, 2023, 165 : 343 - 351
  • [46] Clinicopathological factors associated with survival in patients with breast cancer brain metastasis
    Li, Rong
    Zhang, Kui
    Siegal, Gene P.
    Wei, Shi
    HUMAN PATHOLOGY, 2017, 64 : 53 - 60
  • [47] The Effects of Postoperative Neurological Deficits on Survival in Patients With Single Brain Metastasis
    Medikonda, Ravi
    Jackson, Christopher M.
    Feghali, James
    Lim, Michael
    OPERATIVE NEUROSURGERY, 2020, 19 (06) : 628 - 634
  • [48] Survival and prognostic factors in patients with brain metastasis: Single center experience
    Ekici, Kemal
    Temelli, Oztun
    Dikilitas, Mustafa
    Dursun, Ibrahim Halil
    Kaplan, Nihal Bozdag
    Kekilli, Ersoy
    JOURNAL OF BUON, 2016, 21 (04): : 958 - 963
  • [49] Treatment and survival of patients with small cell lung cancer and brain metastasis
    Chiang, Chi-Lu
    Yang, Huai-Che
    Liao, Ying-Ting
    Luo, Yung-Hung
    Wu, Yuan-Hung
    Wu, Hsiu-Mei
    Chen, Yuh-Min
    JOURNAL OF NEURO-ONCOLOGY, 2023, 165 (02) : 343 - 351
  • [50] Survival rates for breast cancer patients with brain metastasis treated with radiation
    Simonsen, M.
    Offersen, B. Vrou
    Jensen, A. Bonde
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1007 - S1010